Ascletis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Ascletis Pharma CEO'su Jinzi Jason Wu, Apr2013 tarihinde atandı, in görev süresi 11.58 yıldır. in toplam yıllık tazminatı CN¥ 57.67M olup, şirket hissesi ve opsiyonları dahil olmak üzere 99.9% maaş ve 0.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 52.75% ine doğrudan sahiptir ve bu hisseler $ 117.22M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 6.6 yıldır.

Anahtar bilgiler

Jinzi Jason Wu

İcra Kurulu Başkanı

CN¥57.7m

Toplam tazminat

CEO maaş yüzdesi	99.9%
CEO görev süresi	11.6yrs
CEO sahipliği	52.7%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	6.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jinzi Jason Wu'un ücretlendirmesi Ascletis Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥258m
Mar 31 2024	n/a	n/a	-CN¥202m
Dec 31 2023	CN¥58m	CN¥58m	-CN¥145m
Sep 30 2023	n/a	n/a	-CN¥194m
Jun 30 2023	n/a	n/a	-CN¥243m
Mar 31 2023	n/a	n/a	-CN¥279m
Dec 31 2022	CN¥23m	CN¥22m	-CN¥315m
Sep 30 2022	n/a	n/a	-CN¥246m
Jun 30 2022	n/a	n/a	-CN¥176m
Mar 31 2022	n/a	n/a	-CN¥188m
Dec 31 2021	CN¥20m	CN¥20m	-CN¥199m
Sep 30 2021	n/a	n/a	-CN¥234m
Jun 30 2021	n/a	n/a	-CN¥269m
Mar 31 2021	n/a	n/a	-CN¥239m
Dec 31 2020	CN¥11m	CN¥11m	-CN¥209m
Sep 30 2020	n/a	n/a	-CN¥155m
Jun 30 2020	n/a	n/a	-CN¥100m
Mar 31 2020	n/a	n/a	-CN¥98m
Dec 31 2019	CN¥11m	CN¥11m	-CN¥96m

Tazminat ve Piyasa: Jinzi Jason 'nin toplam tazminatı ($USD 7.96M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Jinzi Jason şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jinzi Jason Wu (60 yo)

11.6yrs

Görev süresi

CN¥57,668,000

Tazminat

Dr. Jinzi Jason Wu Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScience Co., Ltd.a pharmace...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jinzi Jason Wu	Founder	11.6yrs	CN¥57.67m	52.75% $ 117.2m
Hejingdao Wu	Senior VP of Operations & Executive Director	no data	CN¥2.85m	0.12% $ 262.7k
Yuemei Yan	Senior Vice President of Clinical Development Operations	3.7yrs	Veri yok	Veri yok
Kristjan Gudmundsson	Senior Consultant & Head of Discovery	11.5yrs	Veri yok	Veri yok
George Hill	Senior Consultant & Chief Medical Advisor	7.2yrs	Veri yok	Veri yok
John Gargiulo	Chief Business Officer	2.4yrs	Veri yok	Veri yok
Ming Fai Chung	Company Secretary	2.3yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: ASCL.F 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jinzi Jason Wu	Founder	10.8yrs	CN¥57.67m	52.75% $ 117.2m
Hejingdao Wu	Senior VP of Operations & Executive Director	6.7yrs	CN¥2.85m	0.12% $ 262.7k
Jiong Gu	Independent Non-Executive Director	6.6yrs	CN¥385.00k	Veri yok
Yizhen Wei	Independent Non-Executive Director	6.6yrs	CN¥385.00k	Veri yok
Lin Hua	Independent Non-Executive Director	6.6yrs	CN¥385.00k	Veri yok

6.6yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ASCL.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).

Ascletis Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer

Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022

Recent updates

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F

Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022

Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022

Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer

Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022

Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application

Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration

Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication

Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022

Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022

Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021

Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

Ascletis Pharma Inc. Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Ascletis Pharma Inc. Announces U.S. Ind Approval of Asc22, A Subcutaneously Administered Pd-L1 Antibody for Functional Cure of Chronic Hepatitis B

Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F

Ascletis Pharma Inc. Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-COV-2 Virus